Welcome to N4 Pharma
We’re N4 Pharma, a specialist pharmaceutical company developing a novel silica nanoparticle delivery system for vaccines and therapeutics for licensing to pharmaceutical and biotech partners. This nanoparticle has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines.
Information for investors
Are you an investor? Visit the dedicated area of the website to view information on the AIM rule 26, company presentations and reports. The latest regulatory news updates are also available.
Latest news and updates
Our CEO, Nigel Theobald, recently provided an update on our Nuvec® program following the release of our interim results. You can watch the full interview with Proactive London's Andrew Scott below or visit the website: [...]
N4 Pharma has been featured in the latest issue of BioPharm International.